Sunesis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company also engages in developing TAK-580, a pan-Raf inhibitor program in combination with various anticancer agents for the treatment of advanced solid tumor cancers in adult patients; SNS-510, which is in preclinical pharmacology and toxicology studies for the treatment of solid tumor and hematologic malignancies; and vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). In addition, it is developing vosaroxin, which is in Phase 2 trial with decitabine for treatment of diagnosed acute AML or myelodysplastic syndrome (MDS); Phase 1/2 trial with azacitidine for treatment of MDS; Phase 2 trial with infusional cytarabine for treatment of AML; Phase 1/2 trial in adult patients with previously treated intermediate-2 or high-risk MDS; and Phase 1/2 trial with cytarabine tested as consolidation therapy. The company has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SNSS
CUSIP86732860
Phone650-266-3500
Debt
Debt-to-Equity RatioN/A
Current Ratio1.82
Quick Ratio1.82
Price-To-Earnings
Trailing P/E Ratio-1.57
Forward P/E Ratio-2.48
P/E GrowthN/A
Sales & Book Value
Annual Sales$670,000.00
Price / Sales122.98
Cash FlowN/A
Price / CashN/A
Book Value$0.02 per share
Price / Book114.00
Profitability
EPS (Most Recent Fiscal Year)($1.45)
Net Income$-35,450,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-125.59%
Miscellaneous
Employees34
Outstanding Shares36,140,000
Market Cap$84.56 million
Sunesis Pharmaceuticals (NASDAQ:SNSS) Frequently Asked Questions
What is Sunesis Pharmaceuticals' stock symbol?
Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."
How were Sunesis Pharmaceuticals' earnings last quarter?
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) issued its quarterly earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.24) by $0.04. View Sunesis Pharmaceuticals' Earnings History.
When is Sunesis Pharmaceuticals' next earnings date?
What price target have analysts set for SNSS?
5 equities research analysts have issued 12 month price objectives for Sunesis Pharmaceuticals' shares. Their forecasts range from $2.48 to $7.00. On average, they anticipate Sunesis Pharmaceuticals' stock price to reach $4.4933 in the next twelve months. This suggests a possible upside of 97.9% from the stock's current price. View Analyst Price Targets for Sunesis Pharmaceuticals.
What is the consensus analysts' recommendation for Sunesis Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sunesis Pharmaceuticals in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sunesis Pharmaceuticals.
What are Wall Street analysts saying about Sunesis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Sunesis Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. " (8/11/2018)
- 2. Cantor Fitzgerald analysts commented, "SNS-062 Data Now 3Q18. SNSS disclosed that it now expects to complete the Phase Ib trial of SNS-062 in fall 2018, which we interpret as early 4Q18, though it could be late 3Q18. The second dose cohort (50 mg) has not yet completed, but since a Phase Ia in healthy volunteers was run, our expectation has been that it would not take many doses to identify the Phase II dose (RP2D). While the reasons for the delay (rapidly progressing patient, non-drug related AE) are understandable, we think the disclosure could cause the shares to pull back." (3/8/2018)
- 3. Cowen Inc analysts commented, "Sunesis reported Q3 Net loss of $9.9MM and pro forma September 30 cash of." (11/2/2017)
Who are some of Sunesis Pharmaceuticals' key competitors?
Some companies that are related to Sunesis Pharmaceuticals include Minerva Neurosciences (NERV), Seres Therapeutics (MCRB), Innate Pharma (IPHYF), Avid Bioservices (CDMO), Kezar Life Sciences (KZR), resTORbio (TORC), Paratek Pharmaceuticals (PRTK), Corium International (CORI), Sienna Biopharmaceuticals (SNNA), Kala Pharmaceuticals (KALA), Selecta Biosciences (SELB), Catalyst Pharmaceuticals (CPRX), Mersana Therapeutics (MRSN), CELYAD SA/ADR (CYAD) and BIOFRONTERA AG/ADR (BFRA).
Who are Sunesis Pharmaceuticals' key executives?
Sunesis Pharmaceuticals' management team includes the folowing people:
- Mr. Dayton Misfeldt, Interim CEO & Director (Age 44)
- Mr. William P. Quinn, Sr. VP of Fin. & Corp. Devel. and CFO (Age 47)
- Mr. Daniel N. Swisher Jr., Strategic Advisor (Age 55)
- Mr. Gene C. Jamieson, VP of Technical Operations
- Dr. Judith A. Fox Ph.D., Chief Scientific Officer
Has Sunesis Pharmaceuticals been receiving favorable news coverage?
Media stories about SNSS stock have trended somewhat positive recently, according to Accern. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sunesis Pharmaceuticals earned a news and rumor sentiment score of 0.12 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 48.05 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. View Recent Headlines for Sunesis Pharmaceuticals.
How do I buy shares of Sunesis Pharmaceuticals?
Shares of SNSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sunesis Pharmaceuticals' stock price today?
One share of SNSS stock can currently be purchased for approximately $2.27.
How big of a company is Sunesis Pharmaceuticals?
Sunesis Pharmaceuticals has a market capitalization of $84.56 million and generates $670,000.00 in revenue each year. The biopharmaceutical company earns $-35,450,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. Sunesis Pharmaceuticals employs 34 workers across the globe.
How can I contact Sunesis Pharmaceuticals?
Sunesis Pharmaceuticals' mailing address is 395 OYSTER POINT BOULEVARD SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-3500 or via email at [email protected]
MarketBeat Community Rating for Sunesis Pharmaceuticals (NASDAQ SNSS)
MarketBeat's community ratings are surveys of what our community members think about Sunesis Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNSS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNSS will underperform the S&P 500 over the long term. You may vote once every thirty days.
